treatment, tolerance developed to the acute effects of intravenous alprazolam on CBF, memory, and plasma epinephrine. There were no consistent regional neuroanatomic differences in the CBF effects of acute alprazolam, or in the development of tolerance to these effects, and no correlations between the various measures of acute alprazolam effects on either test day. [Neuropsychopharmacology 8:161-169, 1993] drugs, renewed concerns about the occurrence of abuse, tolerance, and dependence with long-term dosing has resulted in recent increased regulation of benzodiaze pine (Brahams 1990) .
Although numerous studies have examined the acute pharmacodynamic and pharmacokinetic effects of benzodiazepines in normal and anxious human sub jects, fewer studies have examined the effects of chronic administration of benzodiazepines in human subjects, beyond their therapeutic efficacy in anxious patients (reviewed in McLeod et al. 1988) . Relatively little work has been done directly measuring the effects of ben zodiazepines in neuroanatomically discrete brain regions. Three studies have examined the acute effects of benzodiazepines on cerebral blood flow (CBF) (Mathew et al. 1985 (Mathew et al. , 1991 and glucose metabolism (de Witt et al. 1991) in normal human subjects, and one study has examined the effect of 3 weeks of chronically administered benzodiazepine on cerebral glucose me tabolism in anxious human subjects (Buchsbaum et al. 
1987).
This study investigated the acute intravenous and 0893-133X/93/$6.00 chronic (oral) effects of currently the most widely prescribed benzodiazepine, alprazolam, on CBF mea sured by positron-emission tomography (PET), memory, sedation, and plasma catecholamines (norepinephrine and epinephrine). By repeating the acute alprazolam challenge after 1 week of continuous treatment with oral alprazolam, we examined the development of tolerance using multiple pharmacodynamic measures and inves tigated whether there were regional neuroanatomic differences in the development of tolerance to the CBF effects of acute alprazolam administration.
METHODS

Subjects
Eight right-handed males ranging in age from 18 to 25 years were recruited by advertisement in the Univer sity of Washington Health Sciences Center. Volunteers were employees or students in the health sciences. They were in good mental and physical health currently and by history. Psychiatric history was obtained by Struc tured Clinical Interview for DSM-III-R (SCID), volun teer version. Patients had not taken medication for the past month and had no history of exposure to benzodi azepines or other psychotropic medications. Alcohol use histories indicated three subjects never drank, two drank rarely (once per month), and three drank on a more regular "social" basis (two to three times weekly) but did not meet SCID criteria for alcohol abuse or de pendence.
Experimental Design
The design of the study is presented in Figure 1 . Sub jects ingested nothing by mouth after midnight on the night before testing and came to the PET suite at 8 A.M. 
Positron-Emission Tomography Conditions
All the PET studies were done with a Scanditronix SP-3000, which had been considerably modifIed. This tomograph is a whole-body time-of-flight machine with BaF crystals that is particularly well suited for the high count rate studies done with bolus injection of 0 1 5 wa· ter. The images were reconstructed with a resolution of 10 mm. The subjects were positioned carefully, usi ng a lateral skull x-ray, and the head was constrained with a customized polyurethane foam head holder and ther· moplastic face mask. Prior to injection of any tracer, an attenuation data set was acquired with a rotating source for 40 minutes. This was used later during im· age reconstruction to correct the emission data ap propriately. Before the attenuation scan, an intravenous catheter was placed in the antecubital fossa on the right and a radial arterial catheter was placed on the left. A calibration vial containing Ge68 was in the fIeld of view and an aliquot from the vial was counted in the gamma counter for cross-calibration between the counter and minutes that data was acquired during each PET scan, subjects performed a simple visual continuous performance task by pressing a button with their right hand whenever the letter liB" appeared on a computer screen overhead (A, B, C, and D were shown in ran dom order, one letter every 3 seconds). This task as sured that subjects were awake during the scan and sub jects were also kept awake between scans by being engaged in emotionally neutral conversation. Arterial blood samples were obtained every 2 seconds via an automated blood sampling machine (Graham and Lewellen 1988 ) and a fmal sample for plasma catechola mines and alprazolam level was obtained at the end of the 2-minute scan. Cerebral blood flow values were cal culated using the Kety method modilied by Herscovitch with a permeability surface area product for water of 1.04 ml/gm/min (Herscovitch et al. 1984) .
Positron-Emission Tomography-Magnetic Inonance Imaging
On the day prior to a study, the subject came to the PET suite and had the head holder and thermoplastic mask molded to fIt his face. He was taken to the MRI suite where a sagittal MRI was obtained, and from it the oblique transverse plane containing the intercom missural (AC-PC) line was determined. A plastic card, taped to the forehead of the mask, bearing three evenly spaced oil-fIlled tubes, provided landmark points on the sagittal MR!. Three parallel MRI slices were ob tained, 7.2 mm below and 7.2 mm and 21.6 mm above tbeAC-PC plane. These slices were selected to include neuroanatomic areas rich in benzodiazepine and/or im plicated by preclinical autoradiographic studies of ben zodiazepine effects (Ableitner et al. 1985; Nehlig et al. 1987), including neocortex, striatum, thalamus, mid brain, and cerebellum. On the next day, in the PET suite, the PET gantry was rotated to bring PET slices parallel to the oblique transverse AC-PC plane, and the table was moved axially to bring the three PET planes (on 14.4 mm centers) into register with the MRI planes.
Lateral skull x-rays were used to confIrm the position, using as landmarks the sella turcica and a metal-rod replica of the MR! landmarks taped to the mask. In this manner, coregistration error was reduced to slippage lithe rest position of the skull in the tightly fItted mask. Figure 2 depicts the three MRI slices of one subject, showing all regions of interest obtained.
Other Measures
Memory effects were measured using a simple word list me thod developed by Weingartner and validated
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as being benzodiazepine sensitive in prior studies (Roy Byrne et al. 1987) . Four tasks measured immediate rec ognition memory, free recall, and delayed recognition of twelve categorically similar words, six of which were repeated twice (perfect score = 36). Self-rated sedation was measured by asking patients to respond orally to fIVe separate 0 to 100 analogue-type scales using differ ent synonyms for alert (0) and drowsy (100). This oral modifIcation of a well-validated visual analogue scale method (Bond and Lader 1974) has not been validated and may have less sensitivity to benzodiazepine effects than the visual scale, but was necessary since subjects had to remain in the scanner and were unable to manipulate pen and paper. The mean score for the fIve scales was used as the measure. Plasma norepineph rine and epinephrine were measured in duplicate using a single-isotope enzymatic assay (Evans et al. 1987) , and plasma alprazolam levels were measured by high performance liquid chromatography (Smith and Kroboth 1987) .
Statistical Analysis
Statistical analysis was done to determine separate within-session drug effects for each test day and then to compare within-session effects across days. One-way repeated-measures analysis of variance (ANOV A) was performed for each measure on the data from Day I, comparing four sets of values grouped by time interval (0, 15, 45, and 75 minutes after injection); a signifIcant effect of time interval was interpreted as indicating an alprazolam effect. The same analysis was performed on the data from Day 8. Two-way repeated-measures ANOV A was also performed for the same data from both days, compar ing eight sets of values grouped by time interval and by day; a signifIcant interaction between time interval and day indicated that the observed drug effect (change over time compared to baseline) was signifIcantly differ ent on the two days, suggesting tolerance to alprazo lam's effect.
In addition, the two sets of baseline (time interval O) values for each measure were compared by ANOV A; a signifIcant decrease on Day 8 as compared to Day 1 was interpreted as a possible indication of a "floor" effect that could prevent a further acute drop in the value, contributing to the appearance of alprazolam tolerance on Day 8. Analyses were repeated for CBF for individual neu roanatomic regions, with raw CBF values "normalized" to the whole-slice CBF (i.e. , region CBF/slice CBF), to factor out contributions of global CBF changes to in dividual regional changes.
For Day 1, for each measure, the maximum change from baseline observed at the three subsequent time intervals was calculated; correlation coefficients com paring these maximal effects for every pairing of mea sures were calculated to determine whether the mea- sures were independent. The same procedure was followed for Day 8 and for the difference between Day 1 and Day 8.
Complete data on CBF was available for only six of eight subjects. Data for one subject on Day 1 was lost during computer transformation of raw activity counts so that Day 8 data was of little use. For another subject, the CBF value on Day 1 baseline was judged to be in valid, being only 60% of the value of all other subjects' Day 1 baselines. This resulted in this subject's subse quent CBF values obtained after alprazolam being sub stantially higher than this baseline (in contrast to all other subjects). Conversely, behavioral, cognitive, and catecholamine effects for this subject were similar to those of all other subjects (i.e., in the opposite direc tion from CBF changes), further suggesting that this baseline value was erroneous. Because of the loss of data for two subjects, CBF data was analyzed separately (n = 6) from data for memory, sedation, plasma cate· cholamine, and plasma alprazolam level (n = 8).
I{ESULTS
As expected, plasma alprazolam levels rose signifIcantly on both days following injection (Fig. 3) , indicated by a signifIcant time-interval effect (F = 12.5, P < 0.000l, Day 1; F = 112.1, P < 0.00001, Day 8). Peak levels oc· curred at the fIfteen-minute time interval, and declined only slightly (10% to 30%) over the next hour. Levels were higher at all times on Day 8, and there was no signifIcant interaction between time and day (F = 0.93, P = ns), indicating the absence of tolerance to the ac ute effect of plasma level itself.
Self-rated sedation also signifIcantly increased over baseline (predrug) values on both days following al· 60r;::= == == =�--------------, Tolerance was observed, in contrast, for plasma epinephrine (Fig. 4 ) and for memory (Fig. 5) . Plasma epinephrine significantly decreased from baseline (predrug) values on Day 1 (time-interval effect: F = 13.24, p< 0.0001), but not on Day 8 (time-interval effect: f = 0.10, P = ns). Tolerance was suggested by a signifIcant time-interval x day-interaction effect (F = 7.7, P <. 001). Baseline values for plasma epinephrine were not significantly lower on Day 8 (F = 2.98, P = lIS). Memory performance (Fig. 5 ) significantly de creased from baseline (pre drug) performance values on Day 1 (time-interval effect: F = 1 0.0, P < 0.001), but not on Day 8 (time-interval effect: F = 1. 5, P = ns). Toler lICe was suggested by a significant time-interval x day interaction effect (F = 3.5, P < 0.05). Baseline values for memory performance were highly similar on both days If = 0.07, P = ns). measures ANOVA: Day 1 and Day 8), for interaction effects between time interval and day (two-way ANOV A) (indicating differential acute alprazolam effects before and after chronic alprazolam treatment), and for differences in baseline CBF between Day 1 and Day 8 (ANOV A). On Day 1, absolute CBF values significantly decreased in all areas on slice 1, in all areas but striatum on slice 2, and only in the occipital lobes (p < 0.10) on slice 3. Decreases for whole-brain CBF rang ing from 7% to 40% were significant on slices 1 and 2 (Figs. 6 and 7), and close to significant for slice 3 (p = 0.12). On Day 8, CBF values were not significantly de creased by the acute intravenous dose of alprazolam at the p less than 0. 05 level in any area and at the p less than .10 level in only three areas. This lack of effect may be partially the result of signifIcantly lower baseline CBF values on Day 8 that were signifIcantly lower in all areas of slice 2 and nonsigniflcantly lower in all areas of slice 1 (i.e., a "floor" effect). There was, as would be expected from the univariate ANOV A's on Days 1 and 8, a sug gestion of tolerance to benzodiazepine effects on CBF, with a trend for time interval x day interaction for whole brain on slices 1 and 2 (Figs. 6 and 7) . Although a few individual neuroanatomic regions showed evi dence (p < 0.10) of interaction, the majority of areas on both slices 1 and 2 had low but nonsigniflcant interac tion p-values (0.10 to 0.20), and all areas on slice 3 had high p-values (0.36 to 0.67). This suggested that toler ance to the benzodiazepine effect on CBF is a general phenomenon affecting each slice, without a speciflc fo cus in any particular region. Therefore, additional ANOV As were performed on regional CBF values nor· malized for the respective whole-slice CBF (region, whole-slice). This analysis gave no evidence of any signiflcant regional tolerance; moreover, it eliminated all previously signifIcant acute effects as well (p > 0.40 for all analyses), suggesting that acute regional effects were all components of a more global effect on brain CBF. There were no correlations between alprazolam· induced changes in any of the variables on Day 1, Day 8, or the Day 8 minus Day 1 difference.
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DISCUSSION
In this study, intravenous administration of a fairly large, sedating dose of alprazolam resulted in acute rine, whole-brain CBF, and self-rated alertness. After 1 week of oral alprazolam treatment at standard anxio lytic doses (2 mg/day), tolerance developed to the acute alprazolam decreases on the frrst three measures, but not to the sedative effects, using a crude self-report mea sure. However, all subjects defmitely appeared less sedated behaviorally during the second acute study.
Furthermore, tolerance to the sedative effects of alprazo lam has been previously observed following 3 days of administration of 3 mg and 6 mg daily doses in healthy volunteers (Fleishaker et al. 1989 ).
Changes in CBF following acute alprazolam treat ment appeared fairly uniform throughout the brain regions sampled, and tolerance on acute rechallenge after a I-week treatment was suggested by data from slices 1 and 2. No specmc regional focus of the CBF effect or tolerance to it was indicated after normalizing CBF values to whole-brain (slice) CBF. All regional effects evident when the regions were analyzed separately dis appeared after the values were divided by the CBF value of the corresponding slice, confrrming that such effects were entirely attributable to changes in global CBF. We did not observe the consistent difference between cor tical and subcortical benzodiazepine effects observed by de Witt et al. (1991) , although the only region in slice 2 not showing acute effects was the striatum. Regional differences following acute diazepam noted by one group (Mathew et al. 1986) were not replicated by this same group (Mathew et al. 1991 ) when a 20% higher dose of diazepam was injected rapidly (over 1 minute as in our study) instead of more slowly (over 5 minutes).
It is possible that regional differences in this study might have been more apparent with a lower dose of al prazolam.
The decrease in whole-brain CBF seen with acutely administered alprazolam is interestingly similar to the decrease in whole-brain glucose metabolism seen fol lowing cocaine administration (London et al. 1990 ).
Since glucose metabolism is usually, although not al ways, tightly coupled to blood flow, and since alprazo lam is also a euphoriant with addictive potential in vul nerable individuals (Ciraulo et al. 1988) , this is consistent with the suggestion by London et al. that euphoriant and/or addictive drugs may lower whole brain metabolism.
Following 1 week of alprazolam treatment, de creases in baseline CBF were present throughout slice 2, suggesting that tolerance may have been in part a "floor" effect. Although this might be due to oral al prazolam treatment already producing near-maximum CBF decreases in some patients, it is also possible that lower CBF during the second scan was due to lower patient stress, greater familiarity with the procedure, or the antianxiety effects of alprazolam. A placebo group or cross-over design would be required to attribute this NEUROPSYCHOPHARMACOLOGY 1993-VOL. 8, NO.2 definitively to maximal alprazolam effects. The reason for failure to find differences in baseline CBF values on slices 1 and 3 is unclear but it might be related either to true neuroanatomic differences, or to technical vari· ation in data acquisition/reconstruction with different scanner slices (slice 2 was the cross-plane slice).
Our absolute CBF values were somewhat lower than those usually reported in the literature. This may be due to our relatively crude method of scatter correc· tion. Nonetheless, all values were similarly determined and were quite consistent for individual subjects across regions and slices. Failure to find correlations between different benzodiazepine effects across individuals is not unusual, even in samples of far greater size than ours. Although a within-subjects analysis can demon· strate a statistically significant correlation (Bond and Lader 1983) , individual variability of baseline levels and a nonlinear response due to "floor" and "ceiling" effects often prevents between-subjects correlations from reaching signmcance.
In conclusion, this study has demonstrated that tolerance to the effects of acutely administered alprazo· lam develops in normal subjects after 1 week of con· tinuous treatment with anxiolytic doses of oral alprazo· lam. Tolerance appeared to be nonspecifically present across multiple pharmacodynamic measures and was evident even without controlling for the higher alprazo· lam blood levels that subjects had on the second test day. No evidence of regional neuroanatomic differences in either acute alprazolam effects on CBF or regional differences in tolerance to these acute effects as has been seen in preclinical studies (Laurie and Pratt 1989) was evident, perhaps due to the higher acute doses em· ployed.
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